 |
|
|
|
 |
|
|
| Article 1 to 10 out of 63 concerning Galapagos NV
|
-
NIH extends agreement with Galapagos
(07/23/2008)
Galapagos NV announced that the U.S. National Institutes of Health (NIH) have extended their agreement with Galapagos' service division BioFocus DPI for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) until December 2010. ...
-
Galapagos announces first milestone in osteoporosis collaboration with Lilly
(07/21/2008)
Galapagos NV announced that it has reached the first milestone in its osteoporosis collaboration with Eli Lilly and Company, triggering a payment of EUR1 million from Lilly.In December 2007, Lilly and Galapagos initiated a program to develop new ...
-
Boehringer Ingelheim licenses drug targets from autoimmune collaboration with Galapagos
(07/18/2008)
Galapagos NV announced that Boehringer Ingelheim has exercised its right to license two drug targets from the autoimmune research agreement with Galapagos' BioFocus DPI service division, resulting in a milestone payment to Galapagos.This is the ...
-
Galapagos signs new compound management agreement
(06/30/2008)
Galapagos NV announces that its service division BioFocus DPI will provide compound management and related services to Sepracor Inc. Total contract value for Galapagos is EUR1 million. Under the terms of the agreement, BioFocus DPI will receive, ...
-
Galapagos announces milestone payment of EUR0.8 million in osteoarthritis alliance with GlaxoSmithKline
(06/17/2008)
Galapagos NV announced that it has reached two new milestones in its multi-year drug discovery alliance with GlaxoSmithKline in osteoarthritis, triggering a payment of EUR0.8 million from GSK.In June 2006, GSK's Center of Excellence for External ...
-
California Stem Cell and Biofocus DPI to collaborate in ALS Association-funded research using human motor neurons
(05/23/2008)
California Stem Cell, Inc. (CSC) will supply international drug discovery organization BioFocus DPI, the service division of Galapagos, with its MOTORPLATE(TM) 96 assay-ready well plates, containing motor neuron progenitors (MNPs) derived from human ...
-
Galapagos signs research agreement with UCL
(05/20/2008)
Galapagos NV announced that is has signed a drug discovery research agreement with UCL (University College London). Galapagos' BioFocus DPI service division will perform medicinal chemistry services for a UCL research project. It is also intended ...
-
Galapagos and Allergan enter drug discovery collaboration
(05/07/2008)
Galapagos NV announced today that Galapagos' service division, BioFocus DPI, will provide hit-finding services for multiple Allergan, Inc. targets. Total contract value for Galapagos could reach up to EUR1.3 million over the next 12 months, ...
-
Galapagos licenses clinical rheumatoid arthritis program
(04/18/2008)
Galapagos NV and Enceladus Pharmaceuticals BV announced the in-licensing of Nanocort by Galapagos. Nanocort is a patented liposome-formulation of prednisolone to treat inflammatory diseases, in particular for the acute treatment of flares in ...
-
Galapagos appoints Piet Wigerinck as Senior VP Development
(04/15/2008)
Galapagos NV announced the appointment of Dr. Piet Wigerinck as Senior Vice President of Development. As a member of Galapagos' Executive Team, Dr. Wigerinck will oversee the development of Galapagos' drug candidates, including pre-clinical ...
Additional information
Galapagos NV
Mechelen, Belgium
Company
|
|
|
|
|
|
Top
